@fontev1
Account based inBelgium
About this account
- Account based in
- Belgium
- Connected via
- Belgium App Store
Account-level information from X, not a live location or the device used for a specific post.
Radiation-Oncologist, Ghent University Hospital, Belgium. Associate professor, Ghent University
Ghent
Joined February 2017
- Tweets115
- Following144
- Followers265
- Likes197
Valérie Fonteyne retweeted
Adjuvant RT may finally be back in bladder cancer.
The phase III BART trial shows that modern pelvic IMRT after cystectomy significantly improves locoregional control in high-risk MIBC. 🚨
🇮🇳 Multicenter randomized trial
153 patients
90% received perioperative chemotherapy
🩻 Adjuvant RT vs Observation after radical cystectomy
📌 2-year LRFS
87.1% vs 76.0%
HR 0.43 (P=.04)
📌 2-year DFS
71.6% vs 58.7%
📌 2-year OS
70.4% vs 57.4%
Most striking finding:
❌ No isolated pelvic recurrence after adjuvant RT.
Despite historical concerns, toxicity remained low with modern IG-IMRT:
⚠️ Grade ≥3 acute toxicity: <5%
⚠️ No major increase in severe late toxicity
This is important because pelvic failures after cystectomy are often devastating and rarely salvageable.
The study strongly reopens the discussion around integrating pelvic RT into multimodality care for high-risk bladder cancer, especially in the modern immunotherapy era.
Could adjuvant RT + IO become the next frontier in MIBC?
📖 Full paper in comment ⬇️
#OncoTwitter #MedTwitter #BladderCancer #RadOnc @ASCO @myesmo @esmo_o @OncoAlert
Valérie Fonteyne retweeted
📣 Updated ESMO #ClinicalPracticeGuideline on local & locoregional #ProstateCancer:
✅New imaging modalities: improved diagnosis, staging & risk stratification
✅Updated algorithms: less over-Tx & fewer side-effects
#Oncology #UroOncology #CancerCare #ESMOGuidelines
🔗 ow.ly/Wtv150XKgB1
Valérie Fonteyne retweeted
Just out in @TheLancet: an overview on current approaches to diagnosis and management of prostate cancer.
sciencedirect.com/science/ar…
Valérie Fonteyne retweeted
What a lovely memento of the #BLADDR25 family. Looking forward to #BLADDR26 in #Amsterdam - come & join us - Dec 2-5 2026! @mirrorsmed @issecam #PROSCA25 #RENALC25
Valérie Fonteyne retweeted
DEAR COLLEAGUES
A reminder that #APCCC26 🇨🇭is coming in 2026
This is a Conference is OPEN TO EVERYONE, not just the Panel members and EARLY REGISTRATION is up until February 28, 2026
Awarm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭
REGISTER HERE: apccc.org/apccc-2026/
Event Details:
📍 Palazzo Congressi, Lugano, Switzerland
🎟️ Register here
🎓 Credits requests: SGU – SSU, SSMO, SRO, SGMN
In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and researchers to address complex clinical questions where high-level evidence is limited. Over two days, the world’s leading experts will engage in high-level presentations, debates, and discussions to clarify and conceptualize the current landscape of care, with a focus on areas of controversy or uncertainty. The insights and consensus developed during the meeting are later published in European Urology, helping shape global standards.
Creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer!
@Silke_Gillessen & @AOmlin
@OncoAlert 🚨
@fabioturco92 @Prof_IanD #PROSCA25 @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @DrChoueiri @tompowles1 @brian_rini @nataliagandur
Four years of hard work were rewarded yesterday with a wonderful PhD and PhD defence by @FlorVerghote !
The results of this research contribute to a better understanding of the role of radiotherapy in bladder cancer. Proud to have been your supervisor with @CharlesPraet !
Honoured to had the opportunity to discuss the place of Adjuvant Radiotherapy for bladder Cancer and presenting the results of the Belgian trial supporting this approach!
Motivated to proceed with our ongoing EFFORT trial!
@FlorVerghote @camilleberquin @daandm @uzgent @ugent
I usually don’t post political views but now…. youtu.be/JhkZMxgPxXU
Updated results by @FlorVerghote of the Belgian trial on Adjuvant Radiotherapy for MIBC!
Awaiting the results of the trials by @PaulSargos and @VedangMurthy
@ugent @uzgent @camilleberquin @CharlesPraet @Xristodouleas @BrianBaumannMD
sciencedirect.com/science/ar…
Valérie Fonteyne retweeted
Does SBRT for oligorecurrent #prostatecancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO. Presented by @ChadTangMD at #GU25.
Valérie Fonteyne retweeted
Recap of a first excellent day of the Belgian Urology Conference in Spa! Kudos to @AFSpinoit for the great organization! And endlessly proud of our team 💪🏽 @uzgent @ugent_fge @DrHerve_urology @CharlesPraet @mwaterloos1 @fontev1 #BAU24
Valérie Fonteyne retweeted
For sure underutilized.
⚡ Safe and efficient with many prospective data available.. And many to come!
@VedangMurthy @jnt_khalifa @fontev1 @BrianBaumannMD @Xristodouleas @GETUG_Unicancer – at Bordeaux, France
Valérie Fonteyne retweeted
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24
LINK TO ARTICLE👇👇👇👇👇👇👇👇
sciencedirect.com/science/ar…
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking.
The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting.
The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer.
Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore
Eric Small
Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis
Ana Aparicio
Andrew J. Armstrong
Diogo Assed Bastos
Gerhardt Attard
Karol Axcrona
Mouna Ayadi
Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul
Consuelo Buttigliero
Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng
Kim N. Chi
Caroline S. Clarke
Noel Clarke
Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke
Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun
Felix Y. Feng
Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis
Susan Halabi
Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope
Lisa G. Horvath
Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones
Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal
Fernando C. Maluf 75 76,
@quimmateo
David Matheson 78,
Mika P. Matikainen 79,
Ray McDermott 80,
@DrRanaMcKay
Niven Mehra 82,
@amerseburger
@CaPsurvivorship ,
Michael J. Morris 85,
Hind Mrabti 86,
Deborah Mukherji
@declangmurphy
Vedang Murthy
Shingai B.A. Mutambirwa
@DrPaulNguyen
William K. Oh
@piet_ost
Joe M. O’Sullivan
Anwar R. Padhani
Chris Parker
Darren M.C. Poon
Colin C. Pritchard
Danny M Rabah
Dana Rathkopf
Robert E. Reiter
Raphaele Renard-Penna
Charles J. Ryan
Fred Saad
Juan Pablo Sade
Shahneen Sandhu
Oliver A. Sartor
Edward Schaeffer
Howard I. Scher
Nima Sharifi
Iwona A. Skoneczna
Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki
Mary-Ellen Taplin
Camilla Thellenberg-Karlsson
Derya Tilki
Levent N. Türkeri
Hiroji Uemura
@DrYukselUrun
Claire L. Vale
Neha Vapiwala
Jochen Walz
Kosj Yamoah
Dingwei Ye
Evan Y. Yu
Almudena Zapatero
@AOmlin
Valérie Fonteyne retweeted
We learned a lot about muscle-invasive bladder cancer this past week. Together, these studies suggest that a strategy worth exploring is to further de-intensify surgical lymph node management to reduce surgery-related mortality, while using adjuvant radiation to treat nodes in the ~30% of patients found to have pathologic T3-4 disease.
1. SWOG 1011 (Lerner SP et al NEJM 2024) shows that a more extensive pelvic LN dissection causes more harm than good, even in clinical T3-4 disease. (>10% of patients in extended lymphadenectomy group died within 6 months of randomization.)
2. SWOG 1011 suggest that if we could better manage pelvic LNs in pts with pathologic T3-T4 disease, we might improve cancer control. (HR~2, but we can’t know if a patient is pathologic T3-T4 till after radical cystectomy due to clinical-pathologic discordance problem.)
3. Marcq et al (JCO 2024) from McGill U. suggests that RT to pelvic LN is effective (in intact setting). (Multiple RCTs from Zaghloul M et al suggests RT effective in post-op setting too (most recent in IJROBP 2024)).
4. BART Trial (Murthy V et al ASTRO 2024) from Tata Memorial Hospital suggests that adjuvant radiation after radical cystectomy does not appear to meaningfully increase late toxicity. (Small bowel obstruction rates, our greatest worry, were similar with and without adjuvant RT.)
@slernerbcmedu1 @siadaneshmand @VedangMurthy @docpriyamvada @BrianBaumannMD @TataMemorial @gautiermarcq @WesKassouf @SWOG @PaulSargos @fontev1 @NEJM @IJROBP
Valérie Fonteyne retweeted
Interested in reading the protocol?
pubmed.ncbi.nlm.nih.gov/3720…
Interested in the early results?
Coming soon at a conference near you!
#BladderCancerAwarenessMonth 🧡
@BladderCancerUK @BladderCancerUS @UroDocAsh @shilpaonc @neerajaiims @fontev1
Valérie Fonteyne retweeted
#ESTRO24 @FlorVerghote adding to the emerging role of adjuvant RT for bladder cancer
Intriguing that only 3/14 pts with positive surgical margins had pelvic failures
#radonc
Valérie Fonteyne retweeted
3-year toxicity after moderate hypofractionated radiotherapy: a Belgian phase 3 trial adding to the evidence that moderate hypofractionated radiotherapy is feasible in unselected prostate cancer patients.
Teamwork @uzgent @Universiteit Gent
lnkd.in/eMK4k3BJ
Valérie Fonteyne retweeted
Is there a role for stereotactic radiotherapy in selected patients with metastatic castrate-resistant #ProstateCancer? Check out this presentation by @fontev1 @ugent. #GU24 written coverage by @RKSayyid @UofT on UroToday > bit.ly/3Sydip9 @ASCO
